ThetaPal ThetaPal

Manufacturing / Biological Products, Except Diagnostic Substances

Krystal Biotech, Inc.

KRYS

$331.63

+$4.19 (+1.28%)

Price as of Oct 9, 2026 21:08 UTC

10 B

Market Cap (Large Cap)

47%

IV Rank

46.1%

Implied Volatility

Nov 02

Next Earnings

Technical Signals as of Oct 7
Bearish
1 of 7

Trend

  • Above 20-day average $336.15
  • Above 50-day average $339.10
  • Above 200-day average $297.31 · +9.2%
  • Moving averages stacked Not aligned

Momentum

  • Golden cross (50/200) —
  • Momentum cross (20/50) Down · 4d ago

Volume

  • Below-average volume 1.2x avg

Price & Trend

Daily candles with EMA 20, SMA 50. Drag to zoom.

Options Activity & Greeks

Implied volatility, flow, and dealer positioning from the options market.

Put/Call Ratio

0.00

Bullish skew

Implied Volatility

46.1%

1% percentile

IV vs Realized

Options rich

30d HV 31.4%

Options Heat Map

Delta-risk grid for KRYS options across strikes and expirations. Hover any cell for full Greeks.

Loading option chain data...

Insider Trades

0 buys 172 sells
Date Insider Title Type Shares Value Since Trade
Sep 14, 2026 Mason Christopher Grant 471 $0 -3.7%
Sep 14, 2026 Sutherland Everett Rand Grant 1,187 $0 -3.7%
Sep 14, 2026 Sutherland Everett Rand Grant 471 $0 -3.7%
Sep 14, 2026 Mazzacco Catherine Grant 1,187 $0 -3.7%
Sep 14, 2026 Mazzacco Catherine Grant 471 $0 -3.7%
Sep 14, 2026 Mason Christopher Grant 1,187 $0 -3.7%
Sep 14, 2026 Gangolli Julian S Grant 471 $0 -3.7%
Sep 14, 2026 Gangolli Julian S Grant 1,187 $0 -3.7%
Sep 14, 2026 ROSSI DINO A Grant 471 $0 -3.7%
Sep 14, 2026 ROSSI DINO A Grant 1,187 $0 -3.7%

Earnings History

Date Quarter EPS Est. EPS Actual Surprise Result
Aug 10, 2026 Q2 2026 $1.75
Aug 03, 2026 Q2 2026 $1.69
Jun 30, 2026 Q2 2026 $1.69 $1.79 +6.0% Beat
Mar 31, 2026 Q1 2026 $1.45 $1.83 +26.3% Beat
Dec 31, 2025 Q4 2025 $1.44 $1.70 +18.3% Beat
Sep 30, 2025 Q3 2025 $1.11 $2.66 +140.2% Beat
Jun 30, 2025 Q2 2025 $1.15 $1.29 +12.1% Beat

Track KRYS with ThetaPal

Get insider trade alerts, AI portfolio analysis, and options roll recommendations for KRYS and your entire portfolio.